Regeneron: AcTED results posted; new REGN9220 and glaucoma trials registered

Four ClinicalTrials.gov records tied to Regeneron Pharmaceuticals show activity this week, ranging from posted results to newly registered studies.

• The "Anti-VEGF Therapy for Acute Thyroid Eye Disease" trial (AcTED), a Phase 2 study of sub-tenon aflibercept sponsored by Massachusetts Eye and Ear Infirmary with Regeneron as collaborator, posted results on 2026-10-20 after it was terminated due to funding prematurely ending¹. The study enrolled 8 participants before randomizing them to saline plus aflibercept, hyaluronidase plus aflibercept, or hyaluronidase alone¹.
• Regeneron registered a Phase 1/2 trial, "Phase 1 Trial to Investigate the Safety and Tolerability of REGN9220...in Combination With Odronextamab," testing the anti-CD22 x anti-4-1BB bispecific REGN9220 alongside odronextamab (also known as REGN1979, Ordspono™) in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. The study is not yet recruiting, with an estimated enrollment of 36 participants².
• A Phase 2 trial from the University of Miami, the "Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study," lists Regeneron as a collaborator and is testing intravitreal aflibercept injections alongside Ahmed tube surgery for glaucoma. The study is not yet recruiting, with an estimated start of December 2026³, and plans to enroll 100 participants³.
• The Phase 1 imaging study "A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab," sponsored by Regeneron, remains active not recruiting⁴ after enrolling 22 participants at a single site, UMC Groningen in the Netherlands⁴.